| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4d6e2a1e1319bfec90a71b8d6fb3f25d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_074a4570a049adf207f8524628b21892
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e4b5702f58be45b7bf789a68955a7b7c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cbbfc4dcfef12fd90ff9438d40258c65 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-569 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2875
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06 |
| filingDate |
2005-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c69597867011fed295cd397a38ebd72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c7d5b1167e6311965685abcd71fda2c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76185de078c3a5691445ea1cae7de360 |
| publicationDate |
2006-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2006030220-A9 |
| titleOfInvention |
Compositions monovalent for cd40l binding and methods of use |
| abstract |
The invention relates to antibody polypeptides that monovalently bind CD40L. Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity while avoiding potential undesirable effects that can occur with antibodies capable of divalent or multivalent binding of CD40L. In one aspect, a monovalent anti-CD40L antibody polypeptide consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD40L, preferably without substantially agonizing CD40 and/or CD40L activity. In another aspect, the monovalent anti-CD40L antibody polypeptide is a human antibody polypeptide. The invention further encompasses methods of antagonizing CD40/CD40L interactions in an individual and methods of treating diseases or disorders involving CD40/CD40L interactions, the methods involving administering a monovalent anti-CD40L antibody polypeptide to the individual. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9228017-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9096651-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9399680-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9334331-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9340615-B2 |
| priorityDate |
2004-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |